sc002
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02500914)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Delta-like protein 3INHIBITOR
DLL3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Also known as
- sc002
- sc-002
- sc-002
- sc-002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02500914 | Phase 1 | Jun 1, 2015 | Novella Clinical, Stemcentrx |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novella Clinical | For profit | 1 | 0 | 1 | 2015 |
| Stemcentrx | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1